A Phase 2 interventional study of Luspatercept and Placebo in Anemia, sponsored by Bristol-Myers Squibb. Active, not recruiting at 31 sites in 10 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing luspatercept in Anemia — 6 open to participants now, 13 under way, 4 of them phase 3. luspatercept · Anemia.
Among the 19 studies testing luspatercept in Anemia, this one is the 6th largest by planned enrollment, is one of 3 that started in 2022, is one of 10 in phase 2, reaches primary completion later than 8 of the 12 other live ones, and was the 10th registered.
1,812 studies on the registry are indexed under Anemia; 212 are open to participants now.
Browse Anemia studies →6 of the 19 studies testing luspatercept in Anemia are open now, in 4 countries. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Guangdong Second Provincial General Hospital · Sites in China
Ages 18–60
Zhujiang Hospital · Sites in China
Ages 18–70
Weill Medical College of Cornell University · Sites in United States
Ages 18+
Associazione Qol-one · Sites in Italy
Ages 18+
By country, each count listing its studies:
luspatercept: first FDA approval 2019 (REBLOZYL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 117 Anemia studies recruiting now, 66 (56%) set no upper age limit and 33 (28%) stop at 75 or younger; 32 take children under 18; 21 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 12 · Phase 3 5 · Phase 4 1
First in 2011; this study’s year is marked. 3 started in 2022.
This study's planned enrollment of 189 is above the median of 117 across 1,338 interventional studies indexed under Anemia.
Median enrollment 85 across the 19 interventional studies. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 19 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
16 studies in Anemia by Bristol-Myers Squibb: 1 open now, 8 under way, 5 of them phase 3. Of 8 finished, 7 (88%) have results posted.
Among the 16 studies in Anemia by Bristol-Myers Squibb, this one is the 8th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2022, is one of 6 in phase 2, and was the 12th registered.
Bristol-Myers Squibb’s Anemia studies by the year they started, since 2005.
3 of the studies testing luspatercept in Anemia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07663864Guangdong Second Provincial General HospitalLuspatercept for CIA in AML | 2026-12-31 |
| NCT06788691Weill Medical College of Cornell UniversityLuspatercept for Clonal Cytopenias of Uncertain Significance | 2027-02 |
| NCT05664737Bristol-Myers SquibbA Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia | 2027-07-16 |
Add all 3 to your calendar (.ics) → With an account.
Among the 19 studies testing luspatercept in Anemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 16 in Anemia:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the efficacy and safety of luspatercept plus best supportive care (BSC) vs placebo plus BSC on anemia in adult participants with α-thalassemia hemoglobin H (HbH) disease and determine the safety and drug levels in adolescent participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adult participant≥ 18 years with documented diagnosis of A-Thal HbH disease with Transfusion dependence defined as:.
i) TD participant: ≥ 6 RBC units during the 24 weeks prior to randomization. ii) NTD participant:\< 6 RBC units during the 24 weeks prior to randomization(transfusion due to conditions other than A-Thal will not be considered)and, RBC transfusion-free during at least 8 weeks prior to randomization(unless transfusion was required to treat an acute medical condition other than A-Thal) and, mean baseline ≤ 10 g/dL, based on a minimum of 2 measurements ≥ 1 week apart within 4 weeks prior to randomization; hemoglobin values within 21 days post-transfusion will be excluded.
Adolescent participant 12 years to \< 18 years with documented diagnosis of A-Thal HbH disease with transfusion dependence defined as:.
i) TD participant: ≥ 4 RBC events during the 24 weeks prior to enrollment and, no transfusion-free period for > 56 days during the 24 weeks prior to enrollment. Participants must have a history of regular transfusions for at least 2 years.
ii) NTD participant:\< 4 RBC events during the 24 weeks prior to enrollment and RBC transfusion-free during at least 8 weeks prior to enrollment and, mean baseline Hb ≤ 10 g/dL, based on a minimum of 2 measurements ≥ 1 week apart within 4 weeks prior to enrollment, hemoglobin values within 21 days post-transfusion will be excluded.
iii) Participant has (age ≥16 years) or Lansky (age \< 16 years) performance status score ≥ 50 at screening.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Luspatercept
Drug: Placebo
Biological: Luspatercept
Drug: Placebo
Specified dose on specified days
Also known as: BMS-986346, ACE-536, REBLOZYL
Specified dose on specified days
Number of participants with ≥ 50% reduction from baseline in RBC transfusion burden with a reduction of at least 2 units during any continuous 12 weeks during Week 13-48 compared to 12-week interval immediately prior to date of first dose
Adult TD Cohort
Time frame: Up to Week 48
Number of participants with an increase from baseline of ≥ 1.0 grams (g)/decilitre (dL) in mean hemoglobin (Hb) values over the continuous 12-week interval from Week 13 to Week 24 in the absence of RBC transfusion
Adult NTD Cohort
Time frame: Up to Week 24
Dose-limiting toxicities (DLTs) defined as observance of ≥ Grade 3-related hemolytic crises or ≥ Grade 3-related event outside of the known safety profile occurring within the 21 days from their first dose of study therapy
Adolescent TD and NTD Cohorts
Time frame: Up to Week 3
Number of participants with adverse events (AEs)
Adolescent TD and NTD Cohorts
Time frame: Up to 5 years
Pharmacokinetics (PK): Serum concentration of Luspatercept
Adolescent TD and NTD Cohorts
Time frame: Up to Week 108
Number of participants with ≥ 33% reduction from baseline in RBC transfusion burden with a reduction of at least 2 units during any continuous 24-week interval on treatment compared to 24-week interval immediately prior to date of first dose
Adult TD Cohort
Time frame: Up to Week 108
The longest duration with ≥ 50% reduction from baseline in RBC transfusion burden with a reduction of at least 2 units
Adult TD Cohort
Time frame: Up to Week 108
Number of RBC transfusion units from week 1 to week 48
Adult and Adolescent TD Cohorts
Time frame: Up to Week 48
Change from baseline in hemoglobin in the absence of transfusion at Week 24
Adult and Adolescent NTD Cohorts
Time frame: Up to Week 24
The longest duration of an increase from baseline of ≥ 1.0 g/dL in mean hemoglobin values starting from Week 13 in the absence of transfusion
Adult NTD Cohort
Time frame: Up to Week 108
Time Duration with an increase from baseline of ≥ 1.0 g/dL in hemoglobin values in the absence of transfusion within 48 weeks
Adult NTD Cohort
Time frame: Up to Week 48
Number of participants with an increase from baseline of ≥1.0 g/dL in mean Hb values over the continuous 12- week interval in the absence of transfusion
Adult NTD Cohort
Time frame: Up to Week 24
≥ 3 Increase from Baseline in Functional Assessment of Cancer Therapy Anemia Fatigue Subscale (FACT-An FS) Score from Baseline to the period from Week 13 to Week 24
Adult NTD Cohort
Time frame: Up to Week 24
Number of participants with AEs
Adult and Adolescent TD and NTD Cohorts
Time frame: Up to 5 years
Number of participants with laboratory abnormalities
Adult TD and NTD Cohorts
Time frame: Up to 5 Years
Number of participants with immunogenicity
Adult TD and NTD Cohorts
Time frame: Up to 2 Years
Number of participants with ≥ 50% reduction from baseline in RBC transfusion burden during any continuous 24-week interval within 48 weeks compared to the 24-week interval immediately prior to the date of first dose
Adult TD Cohort
Time frame: Up to Week 48
Number of participants with ≥ 33% reduction from baseline in RBC transfusion burden during any continuous 12-week interval compared to the 12-week interval immediately prior to the date of first dose
Adult TD Cohort
Time frame: Up to Week 108
Number of participants with ≥ 33% reduction from baseline in RBC transfusion burden from Week 13 to Week 24 and Week 37 to Week 48 compared to the 12-week interval immediately prior to the date of first dose
Adult TD Cohort
Time frame: Up to Week 48
Number of participants with ≥ 33% reduction from baseline in RBC transfusion burden from Week 1 to Week 24 and Week 25 to Week 48 compared to the 24-week interval immediately prior to the date of first dose
Adult TD Cohort
Time frame: Up to Week 48
Number of participants with ≥ 50% reduction from baseline in RBC transfusion burden from Week 13 to Week 24 and Week 37 to Week 48 compared to the 12-week interval immediately prior to the date of first dose
Adult TD Cohort
Time frame: Up to Week 48
Number of participants with ≥ 50% reduction from baseline in RBC transfusion burden from Week 1 to Week 24 and Week 25 to Week 48 compared to the 24-week interval immediately prior to the date of first dose
Adult TD Cohort
Time frame: Up to Week 48
Change from baseline in total RBC units transfused from Week 1 to Week 24, Week 25 to Week 48, and Week 1 to Week 48
Adult TD Cohort
Time frame: Up to Week 48
The longest duration of RBC transfusion-free period for participants who achieve transfusion-free period of ≥ 12 weeks
Adult TD Cohort
Time frame: Up to Week 108
The longest duration of reduction in transfusion burden for participants who achieve a response (rolling 12-week and 24-week response, both for ≥ 33% and ≥ 50% reduction)
Adult TD Cohort
Time frame: Up to Week 108
Time from first dose to first day of response (rolling 12-week and 24-week response, both for ≥ 33% and ≥ 50% reduction)
Adult TD Cohort
Time frame: Up to Week 108
Change from baseline in number of transfusion events at Week 48
Adult TD Cohort
Time frame: Up to Week 48
Number of participants who achieve RBC transfusion-free period of any continuous ≥ 12 weeks during treatment
Adult and Adolescent TD and NTD Cohorts
Time frame: Up to Week 108
Number of participants who achieve RBC transfusion-free period of any continuous ≥ 24 weeks during treatment
Adult and Adolescent TD and NTD Cohorts
Time frame: Up to Week 108
Time to first transfusion
Adult and Adolescent NTD Cohorts
Time frame: Up to Week 108
Number of transfusions
Adult NTD Cohort
Time frame: Within 48 Weeks
Number of transfusion visits/units
Adult NTD Cohort
Time frame: Within 48 Weeks
Change from baseline in mean hemoglobin values over the continuous 12-week interval from Week 13 to Week 24 and Week 37 to Week 48 in the absence of transfusions
Adult TD and NTD Cohorts
Time frame: Up to Week 48
Number of participants achieving an increase from baseline of ≥1.0g/dL or ≥1.5g/dL in mean Hb values in absence of transfusions from Week 13 to Week 24, Week 37 to Week 48 and during any continuous 12-week window within 24 weeks and 48 weeks
Adult NTD Cohort
Time frame: Up to Week 48
Time from first to last Hb measurement with increase from baseline by ≥ 1.0 g/dL
Adult NTD Cohorts
Time frame: Up to Week 108
Time to the first increase from baseline of ≥ 1.0 g/dL in mean Hb value
Adolescent NTD Cohort
Time frame: Up to Week 48
Number of participants who achieve an increase in mean Hb of >10g/dL values during any continuous 12-week and 24-week interval within 48 weeks in the absence of transfusions
Adult NTD Cohort
Time frame: Up to Week 48
Change from baseline in self-reported health-related quality of life (HRQoL) assessed by physical component summary (PCS) and mental component summary (MCS) of 36-item short-form health survey version2 (SF-36v2) at Week 24 and Week 48
Adult TD and NTD Cohorts
Time frame: Up to Week 48
Change from baseline in non-transfusion dependent β-thalassemia patient-reported outcome (NTDT-PRO) Tiredness/weakness (T/W) and shortness of breath (SoB) domain scores from Week 13 to Week 24 and from Week 37 to Week 48
Adult NTD Cohort
Time frame: Up to Week 48
Change from baseline in FACT-An FS Score at Week 24 and Week 48
Adult NTD Cohort
Time frame: Up to Week 48
Change from baseline in Functional Assessment of Cancer Therapy Anemia Anemia Subscale (FACT-An AS) at Week 24 and Week 48
Adult NTD Cohort
Time frame: Up to Week 48
Number of participants with at least one hemolytic crisis
Adult TD and NTD Cohorts
Time frame: Up to Week 108
Rate of hemolytic crises
Adult TD and NTD Cohorts
Time frame: Up to Week 108
Time to first hemolytic crisis
Adult TD and NTD Cohorts
Time frame: Up to Week 108
Time to second hemolytic crisis
Adult TD and NTD Cohorts
Time frame: Up to Week 108
Change from baseline in hemolysis markers at Week 24 and Week 48
Adult TD and NTD Cohorts:
Time frame: Up to Week 48
Change from baseline in the 6-minute walk test (6MWT) distance at Week 24 and Week 48
Adult NTD Cohort
Time frame: Up to Week 48
Pharmacokinetics (PK): Serum concentration of Luspatercept
Adult and Adolescent TD and NTD Cohorts
Time frame: Up to Week 108
Percent Change from Baseline in Biomarkers for Erythropoiesis at Week 48
Adult and Adolescent TD and NTD Cohorts. The biomarkers for erythropoiesis to be evaluated include sTfR1, erythropoietin (EPO), growth differentiation factor (GDF11), GDF8, GDF15. The change will be measured as a percentage of change from baseline for all the biomarkers.
Time frame: Baseline, Week 48
Percent Change from Baseline in Biomarkers and Parameters for Iron Homeostasis at Week 48
Adult TD and NTD Cohorts. The biomarkers and parameters for iron homeostasis to be evaluated include hepcidin, erythroferrone (ERFE), serum ferritin, liver iron concentration (LIC), myocardial iron, iron chelation therapy (ICT). The change will be measured as a percentage of change from baseline for all the biomarkers.
Time frame: Up to 5 Years
Percent Change from Baseline in HB Variants including HBH
Adult TD and NTD Cohorts.
Time frame: Baseline, Week 48
Change in mean corpuscular volume (MCV) at Week 48
Adult TD and NTD Cohorts
Time frame: Baseline, Week 48
Change in mean corpuscular hemoglobin (MCH) at Week 48
Adult TD and NTD Cohorts
Time frame: Baseline, Week 48
Change in nucleated red blood cells (nRBC) at Week 48
Adult TD and NTD Cohorts
Time frame: Baseline, Week 48
Change in red blood cells (RBC) at Week 48
Adult TD and NTD Cohorts
Time frame: Baseline, Week 48
The longest duration with reduction from baseline in the RBC transfusion burden
Adolescent TD Cohort
Time frame: Up to Week 48
The number of participants with ≥ 50% reduction from baseline in RBC transfusion burden during an continuous 12 weeks during Weeks 13-48
Adolescent TD Cohort
Time frame: Up to Week 48
The number of participants with ≥ 33% reduction from baseline in RBC transfusion burden during an continuous 24 weeks
Adolescent TD Cohort
Time frame: Up to Week 48
Number of participants achieving an increase from baseline of ≥1.0g/dL in mean Hb values in absence of transfusions from Week 13 to Week 24
Adolescent NTD Cohort
Time frame: Up to Week 24
Cumulative time (in weeks) with an increase from baseline of ≥1.0g/dL in mean Hb values in absence of RBC transfusions within 48 weeks
Adolescent NTD Cohort
Time frame: Up to Week 48
Number of participants who achieve an increase in mean Hb of >10g/dL values during any continuous 12-week interval during week 13 to week 48 in the absence of transfusions
Adolescent NTD Cohort
Time frame: Up to Week 48
The longest duration with an increase from baseline of ≥1.0g/dL in mean Hb values in absence of transfusions
Adolescent NTD Cohort
Time frame: Up to Week 48
Number of participants with antidrug antibody (ADA)
Adolescent TD and NTD Cohorts
Time frame: Up to 2 Years
Mean change in biomarkers for hemolysis
Adolescent TD and NTD Cohorts. Biomarkers for hemolysis to be evaluated include total/direct/indirect bilirubin, serum lactate dehydrogenase (sLDH), haptoglobin, reticulocytes and nucleated red blood cells, reticulocyte production index (RPI), and urinary urobilinogen
Time frame: Up to Week 48
Mean change in biomarkers and parameters for iron homeostasis
Adolescent TD and NTD Cohorts. The biomarkers and parameters for iron homeostasis to be evaluated include serum ferritin, liver and myocardial iron content (LIC), (MIC), iron chelation therapy (ICT).
Time frame: Up to 5 Years
Assessment of Hematologic Parameters
Adolescent TD and NTD Cohorts. The hematologic assessments to be evaluated are red blood cell (RBC) count, hemoglobin, hematocrit, reticulocyte count, nucleated red blood cell count, platelet, leukocyte and neutrophile counts, RBC indices, RBC morphology, and Hb variants.
Time frame: Up to Week 48
The change from baseline in the number of health care resource utilization (HCRU)
Adolescent TD and NTD Cohorts
Time frame: Up to 5 Years
Mean change from baseline in Pediatric Quality of Life Inventory (PedsQL) domain scores
Adolescent TD and NTD Cohorts
Time frame: Up to 3 Years
Mean change from baseline EQ-5D-5L utility index
Adolescent TD and NTD Cohorts
Time frame: Up to 3 Years
Mean change from baseline visual analogue scale (VAS) scores
Adolescent TD and NTD Cohorts
Time frame: Up to 3 Years
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Started Dec 2022 (actual). Primary completion is estimated for Jul 2027, 55 months after the start.
Of 58 industry-sponsored phase 2 interventional studies under Anemia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 40. This study's planned 55 months is above that.
Counting every sponsor, half of 88 studies reached it within 28 months; a quarter within 16 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Luspatercept